Ignite Creation Date:
2024-05-05 @ 5:21 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00434122
Status:
COMPLETED
Last Update Posted:
2011-06-02
First Post:
2007-02-09
Brief Title:
Exploratory Study Assessing Synchronisation of Egg Sacs With Degarelix
Sponsor:
Ferring Pharmaceuticals
Organization:
Ferring Pharmaceuticals
Study Overview
Official Title:
A Randomised Assessor-blind Parallel Groups Multi-centre Exploratory Study Assessing the Impact of Subcutaneous Administration of Degarelix 25 mg on Synchronisation of Follicle Cohort Compared to Placebo and Evaluating the Effects of Degarelix 25 mg Started in the Mid-luteal or Early Follicular Phase on Endometrial Receptivity Compared to a Fixed Gonadotrophin Releasing Hormone Antagonist Protocol in Oocyte Donors Undergoing Controlled Ovarian Hyperstimulation for Assisted Reproductive Technologies
Status:
COMPLETED
Status Verified Date:
2011-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main purpose of this clinical research study is to investigate if degarelix can synchronise the growth of the egg sacs in the ovaries and if degarelix has any effect on the lining of the womb
Detailed Description:
For the primary end-point data collected on Stimulation Day 1 the study will compare degarelix 25 mg administered in the mid-luteal phase to placebo administered in the mid-luteal phase
After Stimulation Day 1 the placebo group will be split into two groups a degarelix 25 mg follicular group and a ganirelix 025 mg group
After Stimulation Day 1 the placebo group will be split into two groups a degarelix 25 mg follicular group and a ganirelix 025 mg group
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None